- All G has opened its precision-fermented human lactoferrin to U.S. adult-nutrition and supplement formulations.
- The Sydney company previously scaled recombinant bovine lactoferrin to 60,000 liters through a Chinese contract manufacturer.
All G, a Sydney biotechnology company developing human and bovine milk proteins through precision fermentation, said Nov. 18 that it self-affirmed generally recognized as safe status for recombinant human lactoferrin in U.S. adult nutrition and supplement applications. Self-affirmation reflects the company’s safety conclusion and does not involve FDA review.
The company describes the ingredient as having an amino acid sequence identical to native human lactoferrin and being supplied predominantly in its low-iron apo form. It also retains the four-amino-acid cluster present in the most common natural variant. All G says that combination distinguishes the ingredient from other GRAS human lactoferrins.
For manufacturing, All G programs microbes to produce the target protein in fermentation tanks before purification. Its existing LFX bovine lactoferrin is made at 60,000-liter scale through a contract manufacturer in China, according to CEO Jan Pacas. The company previously said scale-up batches of the human protein also used the apo form.
Human lactoferrin is All G’s second commercial protein after LFX, while recombinant caseins and alpha-lactalbumin remain in development. The determination covers adult nutrition and supplements, not infant formula, and All G has neither described it as submitted to FDA nor disclosed commercial capacity for the human protein. Pacas described the release as the start of a broader portfolio:
“Human lactoferrin is the first of many human milk proteins we will bring to market.”
Jan Pacas, CEO, All G





